Drug Topics

JUNE 17, 2025

Positive results have been announced from a phase 2a clinical trial evaluating the safety, pharmacokinetics and efficacy of PP405 for the treatment of androgenetic alopecia in adult patients, Pelage Pharmaceuticals announced in a release. 1 The company said it plans to initiate phase 3 studies in 2026 to further evaluate the therapy.

Specialty Pharmacies 324

Specialty Pharmacies Compounding Independent Pharmacies Immunization 324

DiversifyRx

JULY 11, 2024

On June 12, 2024, the FDA released a notice stating that it is issuing exemptions from specific requirements of the DSCSA to small pharmacies to go into effect on 11/27/2024 to ensure patient access. The exemption will last until November 27, 2026, for those small dispensers who qualify. The DiversifyRx team is always here to help.

Independent Pharmacies 52

Independent Pharmacies FDA Documentation CPhT 52

Drug Topics

JULY 10, 2025

The FDA has accepted for review a New Drug Application (NDA) for doravirine/islatravir for adult patients with HIV-1 infection that is virologically suppressed on antiretroviral therapy, Merck announced in a release. 1 The FDA set a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. References 1. Subscribe Now!

FDA 247

FDA Vaccines Specialty Pharmacies Compounding 247

ISPE

SEPTEMBER 29, 2023

By 2026, the site will produce 80% of its electricity consumed on-site and aims to be a net-zero greenhouse gas emissions site by 2030. Takeda has reduced CO2 emission by 861 tons. Over the past five years the entire Lessines production site has reduced its operational carbon footprint by 45% or the equivalent of 5,500 tons of CO2.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Labelling Patient Care 52